Dr. Jame Abraham, Director of the Breast Oncology program at Taussig Cancer Institute and Co-Director of the Cleveland Clinic Lerner College of Medicine, as he shares his experience and insight into the importance of clinical trials, their accrual rates and the phase I and phase II trials with Neratinib. @NSABPFoundation @jamecancerdoc
Dr. Jame Abraham discusses the NSABP and breast cancer clincial trials
